Metaxalone Formulation Mitigates Food Effect via Micronization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Metaxalone formulations exhibit a significant food effect, leading to increased bioavailability and altered pharmacokinetic parameters when taken with food, which limits its administration to the fasted state and impairs its utility.
Innovation Solution
A solid oral pharmaceutical formulation comprising micronized and non-micronized crystalline metaxalone with specific dissolution criteria in 0.5% Sodium Lauryl Sulfate or Fasted State Simulated Intestinal Fluid, and pH 4.5 or 6.0 buffer dissolution media, ensuring consistent release profiles that mitigate the food effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If metaxalone is administered in conventional formulations, then the drug can be taken in the fasted state, but the food effect significantly increases bioavailability and alters pharmacokinetic parameters
Solution Approach 1:
The patent modifies the physical and chemical parameters of metaxalone by micronizing the crystalline form and formulating with specific excipients (sodium lauryl sulfate, polysorbate 80, hydroxypropyl cellulose) to achieve a dissolution profile that is insensitive to food effects. The micronized formulation releases 70-85% of the drug within 30 minutes in simulated intestinal fluid, maintaining consistent pharmacokinetics whether taken fasted or fed.
2Ease of operation
If metaxalone is administered with food, then patient convenience is improved, but Cmax increases by 193.6% and AUC increases by 146.4-142.2%
Solution Approach 1:
The patent creates a dissolution profile copy that mimics ideal fasted-state conditions even when administered with food. The micronized formulation with surfactants produces a dissolution curve that releases the drug at a controlled rate independent of gastric emptying variations caused by food, effectively copying the desired pharmacokinetic behavior.
3Reliability
If metaxalone is administered in the fasted state, then pharmacokinetic parameters remain stable, but the utility and convenience of the drug are significantly impaired
Solution Approach 1:
The patent performs preliminary action by pre-micronizing the metaxalone crystals and pre-formulating with dissolution-enhancing excipients before administration. This preliminary processing ensures that the drug is in an optimal physical state for rapid and consistent dissolution, eliminating the need to control dietary conditions at the time of administration.
4Ease of manufacture
If conventional metaxalone formulations are used, then manufacturing is simple, but the drug requires strict fasted-state administration instructions
Solution Approach 1:
The patent uses composite materials by combining micronized metaxalone with a specific matrix of excipients including surfactants (sodium lauryl sulfate, polysorbate 80) and hydrophilic polymers (hydroxypropyl cellulose). This composite formulation approach achieves food-insensitive dissolution while maintaining conventional manufacturing processes for tablets and capsules.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves improved bioavailability and reduced food effect, allowing for effective administration in both fasted and fed states with stable pharmacokinetic parameters, enhancing the drug's utility and patient convenience.
Implementation Method 1
a 640 mg tablet or capsule of said formulation releases at least 50 wt%, 55 wt%, 60 wt%, 65 wt%, or 70 wt% of its metaxalone in 60 minutes when tested in 900 mL 0.5% SLS in water
Data Source
AI summary
Oral dosage forms of metaxalone having improved bioavailability in the fed and fasted states, including dosage forms that employ a reduced dose based on such improved bioavailability.